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Severe Malaria 
and Artesunate 
Treatment, Norway 
To the Editor: Approximately 
8,000 cases of imported falciparum 
malaria are reported in Europe each 
year (1). In a study from Belgium of 
1,743 persons with fever acquired in 
the Tropics, only falciparum malaria 
resulted in deaths (2). 
Until recently, the standard treat-
ment of severe malaria was intrave-
nous quinine (3). Frequent adverse ef-
fects, however, and reports of limited 
clinical efﬁ   cacy in some falciparum 
malaraia–endemic areas preclude its 
usefulness (4). In contrast, artesunate, 
a water-soluble artemisinin derivate 
extracted from the plant Artemesia 
annua (quinghao), is considered safe 
and highly efﬁ  cacious  (4,5). Artesu-
nate has the advantage of rapidly kill-
ing malaria parasites only a few hours 
after invading the erythrocyte, and it 
also reduces cytoadherance (4). Resis-
tance to artesunate at the Cambodia–
Thailand border has been reported, 
but until now artesunate resistance has 
not been considered a problem in most 
malaria–endemic regions (5,6). On the 
basis of 6 randomized controlled trials 
comparing artesunate and quinine, a 
recent Cochrane review recommended 
artesunate as the ﬁ  rst-line treatment in 
adults with severe malaria in such areas 
(7). Similar recommendations were is-
sued by the World Health Organization 
(WHO) in 2006 (8). Also, the European 
surveillance network, TropNetEurope, 
and the Advisory Committee on Malar-
ia Prevention in UK Travelers advocate 
artesunate as the ﬁ  rst-line treatment for 
severe falciparum malaria in travelers 
(9,10). However, the manufacturers of 
intravenous (IV) artesunate have not 
achieved Good Manufacturing Practice 
certiﬁ  cation; currently, the drug is not 
widely used outside Asia. 
In March 2008, an inquiry for 
patients treated with IV artesunate for 
severe falciparum malaria was mailed 
to all major departments of infectious 
diseases in Norway. All departments 
responded, and 9 patients treated from 
February 2006 to May 2008 were 
identiﬁ  ed at 3 centers: 7 at Haukeland 
University Hospital in Bergen, 1 at 
Akershus University Hospital in Nor-
dbyhagen, and 1 at Ullevål University 
Hospital in Oslo. Clinical and labo-
ratory features were retrospectively 
obtained from the medical records. 
Artesunate was produced by Guilin 
Pharmaceutical, Guangxi, China, and 
provided from IDIS Pharmaceutical, 
Weybridge, United Kingdom. 
With the exception of 1 patient 
who had become infected while in 
Myanmar, all patients acquired falci-
parum malaria in West Africa (Table). 
Four patients were Norwegian tour-
ists or businessmen; 4 patients were 
visiting friends and relatives and had 
lived in Norway for 2, 15, 20, and 40 
years, respectively. One patient was a 
pregnant (third trimester) immigrant. 
None of the patients had used antima-
larial chemoprophylaxis. The patients’ 
symptoms fulﬁ  lled up to 5 of the WHO 
criteria for severe malaria: 1 patient had 
cerebral malaria, 5 impaired conscious-
ness, 5 jaundice, 2 shock, 2 renal fail-
ure, 2 hemoglobinuria,1 hematemesis, 
and 8 hyperparasitemia (Table). The 
initial treatment consisted of IV artesu-
nate plus doxycycline (n = 7), IV arte-
sunate monotherapy (n = 1), or IV arte-
sunate plus clindamycin (n = 1). The 
dosing of artesunate was 2.4 mg/kg at 
0 h, 12 h, and 24 h and then daily there-
after. Patient 6 received a 1,200-mg 
loading dose of quinine before transfer 
to one of the study hospitals (Table). 
None of the patients needed exchange 
transfusions. No adverse effects were 
attributed to artesunate, and the preg-
nant patient delivered a healthy child 
at term. The parasitemia level fell be-
low 1% in all patients within 1–2 days. 
Treatment was changed to oral antima-
larial drugs (artemether–lumefantrine, 
meﬂ  oquine, proguanil–atovaquone, or 
quinine) within 2.1 days (mean); all pa-
tients recovered uneventfully and were 
discharged from the hospital within 4.2 
days (mean) (Table). No episodes of 
recrudescence were documented post-
treatment at 4 weeks follow-up; 7 pa-
tients had a negative malaria slide and 
2 patients were not examined for para-
sites but had no clinical recrudescense 
at follow-up.
Our ﬁ  ndings support those of sev-
eral randomized controlled trials per-
formed in Asia and indicate that thera-
py with IV artesunate is safe, induces 
rapid parasite clearing, and usually re-
sults in swift clinical cure. Blood ex-
change transfusion, a labor-intensive 
and potentially hazardous procedure, 
was initially considered for 2 of our 
patients but was deemed unnecessary 
because of the rapid improvement af-
ter artesunate treatment. Artemisinins 
have short half-lives, and there is an in-
creased risk for recrudescence if used 
alone. We gave concurrent IV doxycy-
cline or clindamycin to all but 1 of our 
patients; all patients were treated with 
an oral drug after IV artesunate, and 
recrudescence was not noted. 
A major obstacle for the use of IV 
artesunate is its poor availability out-
side Asia and the fact that its use is not 
approved in many countries. However, 
in the United States, artesunate for in-
fusion may now be obtained as an in-
vestigational drug from the Centers for 
Disease Control and Prevention (www.
cdc.gov/malaria/features/artesunate_
now_available.htm), and in the Europe-
an Union, artesunate recently received 
the Orphan Medicinal Drug Designa-
tion from the European Medicines 
Agency (www.emea.europa.eu/pdfs/
human/comp/opinion/48693207en.
pdf) and may be obtained from IDIS 
Pharma (www.idispharma.com). 
If falciparum malaria is acquired 
at the Cambodia–Thailand border re-
gion, artesunate resistance should be 
considered; except for this region, 
where meﬂ  oquine resistance also is a 
problem, artesunate is considered to 
be an efﬁ   cacious drug with limited 
reports of resistance. In conclusion, 
the current case series suggests that IV 
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artesunate is an efﬁ  cacious and safe 
treatment option in travelers returning 
from West Africa with severe falcipar-
um malaria. 
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Table. Epidemiologic, clinical, and laboratory data from 9 patients with severe falciparum malaria treated with intravenous artesunate,
Norway, 2006–2008* 
Parasitemia level,  %  Patient no. 
(gender/ 
age, y) 
Reason
for travel 
Country 
of disease 
acquisition
WHO severe 
malaria
criteria 
Days from 
symptom 
onset to 
therapy 
Initial
treatment
Day 
0
Day 
1
Day 
2
Day 
3
Day 
4
Length of
hospital
stay, d 
1 (M/37)  Tourism Ghana Impaired
consciousness,
bilirubin† 53, 
hyperparasitemia 
10 AS + D 4< 1 0 ‡ 4
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5 AS + D  15 7 <1 0‡ 3
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bilirubin 241, 
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5 AS + D  20 3 <1 NA 0‡ 5
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3 AS + C 
(patient
pregnant) 
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consciousness,
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6 Quinine
1,200 mg 
loading dose, 
then AS + D 
30 5 0.5‡ 0 7
7 (M/35)  Tourism Myanmar  Impaired
consciousness,
hyperparasitemia 
10 AS 4< 1 0 ‡0 5
8 (F/38)  VFR Liberia Shock 7 AS + D  1 <1‡ 0 0 3
9 (M/55)  VFR Guinea Creatinine 315, 
bilirubin 118, 
hyperparasitemia 
4 AS + D  6 <1 0‡ 4
*WHO, World Health Organization; AS, artesunate; D, doxycycline; VFR, visiting friends and relatives; NA, not available; C, clindamycin. 
†μmol/L (bilirubin reference range 5–25; creatinine reference range 60–105).  
‡Day when intravenous artesunate was discontinued. 
§mmol/L (reference range 0.5–2.2).  
1Current afﬁ  liation:  Aalesund  Hospital, 
Aalesund, Norway.LETTERS
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Bacteremia Caused 
by Mycobacterium 
wolinskyi
To the Editor:  Mycobacterium 
wolinskyi is a rapidly growing my-
cobacterium that belongs to the M. 
smegmatis group, which includes M. 
smegmatis sensu stricto and 2 species 
described in 1999 (M. goodii and M. 
wolinskyi) (1). Only 9 cases of infec-
tion caused by M. wolinskyi have been 
reported (1–3), and these included 3 
cases of bone infection and 1 case of 
infection of a hip prosthesis. All pa-
tients had a history of surgery after 
traumatic injury and all specimens 
were isolated from the surgical wound. 
In our study, we used molecular diag-
nostic tools and report a case of bacte-
remia caused by M. wolinskyi. 
In November 2006, we diag-
nosed non-Hodgkin lymphoma in a 
22-year-old woman. A venous port 
was implanted, and 4 courses of 
rituximab (anti-CD20 monoclonal 
antibody) plus additional chemother-
apy (cyclophosphamide, epirubicin, 
vicristine and prednisolone) were 
administered from December 2006 
through May 2007. No unfavorable 
sequelae occurred after chemotherapy, 
and the tumor showed a complete re-
sponse. In August 2007, we admitted 
the patient to our hospital because of a 
spiking high fever (up to 40°C), chills, 
and pain in the left knee. On physical 
examination, the patient had a tender, 
warm, erythematous, and swollen left 
knee. These symptoms progressed to 
other joints, including the left hip and 
ankle. 
Laboratory data showed a normal 
leukocyte count (3.4 × 109 cells/L). 
The patient’s C-reactive protein level 
increased from 1.13 mg/dL (on the 
day of admission) to 24.95 mg/dL (7 
days after admission). We drew 2 sets 
of blood samples from a peripheral 
vein for culture and incubated these 
cultures (BACTEC 9240 Continuous 
Monitoring Blood Culture System; 
Becton Dickinson, Sparks, MD, USA) 
using BACTEC Aerobic Plus and An-
aerobic Plus medium (Becton Dickin-
son). Within 3 days, the cultures tested 
positive for acid-fast bacilli.
The isolate was identiﬁ  ed by 16S 
rRNA gene ampliﬁ  cation of an 880-bp 
region (corresponding to positions 27–
907), as previously described (4,5). For 
ampliﬁ   cation, we used broad-range 
primers 16S-27f (5′-AGA GTT TGA 
TCM TGG CTC AG-3′) and 16S-907r 
(5′-CCG TCA ATT CMT TTR AGT 
TT-3′). For sequencing 16S rDNA, we 
used either the primer 16S-27f or 16S-
519r (5′-GWA TTA CCG CGG CKG 
CTG-3′). We performed both forward 
and reverse (5′ and 3′) sequencing. For 
accurate analysis of the data, a 492-bp 
variable region (corresponding to posi-
tions 27– 519) was carefully analyzed 
after it was compared with sequences 
of Mycobacterium spp. in the BLAST 
database (www.ncbi.nlm.nih.gov), as 
described (6). The results showed 99% 
similarity between our isolate and 
M. wolinskyi.
A few days later, we obtained 
synovial  ﬂ  uid by needle biopsy and 
cultured samples in BACTEC Aero-
bic Plus and Anaerobic Plus medium 
(Becton Dickinson) and on trypticase 
soy agar. Within 3 days, these cultures 
were also positive for M. wolinskyi. 
Arthroscopically assisted arthrocente-
sis and debridement showed a turbid 
joint and the debrided tissue showed 
inﬂ   ammatory processes within the 
synovial tissue and the presence of ac-
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Figure. Histologic image of debrided tissue of the patient, showing inﬂ  ammatory processes 
within the synovial tissue and the presence of an acid-fast bacillus (magniﬁ  cation ×400, 
acid-fast stain).